This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Theodora Choli-Papadopoulou
Aristotle University of Thessaloniki
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Zinc Finger Protein 217 (ZNF217), a transcription factor and oncogene product, has been found to dysregulate Bone Morphogenetic Protein (BMP) signaling and induce invasion in breast tumors. In this study, the effect of BMP-2 or an active BMP-2 peptide, AISMLYLDEN, on the expression of ZNF217, BMP4 and CDK-inhibitor p21 gene, CDKN1A, was investigated in DPSCs during osteogenic differentiation and in MCF-7 breast cancer cells. BMP-2 peptide reduced the expression of ZNF217 during the first two weeks of osteogenesis and increased the expression of CDKN1A after three weeks. BMP-2 and BMP-2 peptide increased the expression of BMP4 during the first week. The same genes were monitored in MCF-7 after treatment with BMP-2 or different concentrations of BMP-2 peptide. CDKN1A mRNA levels were 10-, 8- and 6-fold higher respectively in MCF-7 cells treated with BMP-2 (100 ng/ml) or BMP-2 peptide (45.2 and 22.6 ng/ml) than in untreated MCF-7. BMP-2 peptide, at a concentration of 22.6 ng/ml reduced ZNF217 expression after 6 h and 12 h. BMP-2 reduced BMP4 expression to undetected levels within 24 h. At appropriate concentrations, BMP-2 and the peptide AISMLYLDEN can be considered as a possible novel therapeutic method in breast tumors with a metastatic tendency to the bones.
Keywords
Zinc Finger Protein 217 (ZNF217), Bone Morphogenetic Protein (BMP), MCF-7 cells
Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
View the published article at Bone Reports.
Version 1
Posted 11 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Theodora Choli-Papadopoulou
Aristotle University of Thessaloniki
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
View the published article at Bone Reports.
Version 1
Posted 11 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Bone Reports.
Zinc Finger Protein 217 (ZNF217), a transcription factor and oncogene product, has been found to dysregulate Bone Morphogenetic Protein (BMP) signaling and induce invasion in breast tumors. In this study, the effect of BMP-2 or an active BMP-2 peptide, AISMLYLDEN, on the expression of ZNF217, BMP4 and CDK-inhibitor p21 gene, CDKN1A, was investigated in DPSCs during osteogenic differentiation and in MCF-7 breast cancer cells. BMP-2 peptide reduced the expression of ZNF217 during the first two weeks of osteogenesis and increased the expression of CDKN1A after three weeks. BMP-2 and BMP-2 peptide increased the expression of BMP4 during the first week. The same genes were monitored in MCF-7 after treatment with BMP-2 or different concentrations of BMP-2 peptide. CDKN1A mRNA levels were 10-, 8- and 6-fold higher respectively in MCF-7 cells treated with BMP-2 (100 ng/ml) or BMP-2 peptide (45.2 and 22.6 ng/ml) than in untreated MCF-7. BMP-2 peptide, at a concentration of 22.6 ng/ml reduced ZNF217 expression after 6 h and 12 h. BMP-2 reduced BMP4 expression to undetected levels within 24 h. At appropriate concentrations, BMP-2 and the peptide AISMLYLDEN can be considered as a possible novel therapeutic method in breast tumors with a metastatic tendency to the bones.
Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Loading...